Abstract

Background Monocytes play an integral role in the development of atherosclerosis. Specific monocyte subsets have been associated with excess cardiovascular events in different patient populations and highlighted as a potential therapeutic target. Objective To compare blood monocyte subsets in patients with focal coronary artery disease (CAD) and diffuse CAD. Methods Three monocyte subsets (CD14 + +CD16-CCR2+ [classical, Mon 1], CD14 + +CD16 + CCR2+ [intermediate, Mon 2] and CD14 + CD16 + +CCR2- [non-classical, Mon 3]) and their aggregates with platelets (monocyte-platelet aggregates, MPAs) were quantified by flow cytometry in 71 CAD patients (subdivided into a group with diffuse CAD [n = 50] and a group with focal CAD [n = 21] based on angiographic coronary artery morphology) and 39 age, sex and risk factor matched controls with normal coronary arteries assessed either invasively or non-invasively using computed tomography coronary angiography (CTCA). Results The clinical characteristics of each group are shown in Table 1. Patients with diffuse CAD had a significantly higher proportion of Mon 2 than patients with focal disease (p = 0.02) or normal coronary arteries (p = 0.03) (Table 2). MPA associated with Mon 2 was also significantly higher in the diffuse CAD group (p Conclusion Patients with diffuse CAD have higher peripheral blood levels of Mon 2 and MPA associated with Mon 2 than patients with focal CAD. Our data support the notion that Mon 2 is related to worse CAD morphology.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.